empoweringmuscleempoweringlives

Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function.

learn more

Now Available | Primary Results of GALACTIC-HF Published in NEJM

Read the primary results from GALACTIC-HF, the Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure, published in the New England Journal of Medicine.

READ MORE ›

cardiovascular disease

Cardiovascular diseases are the leading cause of death in the U.S. and in many places around the world. We’re focused on finding potential treatments for people with heart failure and hypertrophic cardiomyopathy.

NEUROMUSCULAR DISEASE

Neuromuscular diseases can cause loss of muscle function, muscle weakness and fatigue. Our goal is develop potential therapies for people with amyotrophic lateral sclerosis and spinal muscular atrophy.

Press Releases

view all

GALACTIC-HF Primary Results

Download

Pipeline

We have robust pipeline of small molecule muscle activators and inhibitors, including omecamtiv mecarbil, reldesemtiv, CK-274, AMG 594 and CK-601.

Careers

We seek exceptional individuals to join us in our mission to develop the next generation of novel small molecule muscle-directed potential medicines.